PHARMACY

Albertsons takes personal approach to specialty
As it grows its specialty operation, Albertsons has focused on offering patients the option of picking up their prescriptions at their local store to build a more personalized approached.
CMS: Health care spending growth slowed in 2017
As health care spending growth slowed to 3.9%, retail prescription drug spending growth fell to 0.4% — the lowest it's been since 2012, according to a report from the Centers for Medicare and Medicaid services.

FDA approves Catalyst’s Firdapse

Catalyst's Firdapse provides a treatment for Lambert-Eaton myasthenic syndrome — a rare autoimmune disorder.
Albertsons’ empowerment gives pharmacists an edge

DSN’s 2018 Pharmacy Innovator of the Year, Albertsons, has made ensuring pharmacists can practice at the top of their license a cornerstone of its pharmacy strategy — from MTM to prescribing authority and everything in between.
Mallinckrodt to spin specialty generics business off to shareholders

The move would create two independent, publicly traded companies — one of which offers branded specialty products, the other offering niche specialty generics and active pharmaceutical ingredient manufacturing.
AllianceRx Walgreens Prime Survey uncovers medication management habits

In light of the survey results, AllianceRx recommended five steps to improve the experience of managing prescriptions easier.
Walgreens, FedEx partner on next-day Rx delivery nationwide

The companies have launched Walgreens Express, a service that will provide next-day delivery nationwide, as well as same-day delivery in select markets.
TCGRx acquires Parata Systems

The combined company will operate under the Parata Systems brand and be headquartered in Durham, N.C., with additional facilities in Wisconsin.
CVS Caremark unveils new PBM services pricing

CVS Caremark’s new Guaranteed Net Cost pricing model is looking to offer better cost predictability for plan sponsors.
AbbVie, Pfizer ink agreement on Humira biosimilar

Under a licensing agreement AbbVie, Pfizer will be able to launch its Humira biosimilar in the United States Nov. 20, 2023.